Sushil Patel
Known title: DirectorCIK: 0001860609
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
Transaction History
| REPL | ▼ Sell | Open Market | 39,341 | $510K | 8/10/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 600 | $114K | 6/29/2026 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 2,955 | $111K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 300 | $55K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 900 | $166K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 858 | $160K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 300 | $56K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 100 | $19K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 541 | $104K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 881 | $170K | 6/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 1,100 | $204K | 6/29/2026 | View on chart |
| RVMD | ▲ Buy | Grant | 1,191 | $0 | 6/18/2026 | View on chart |
| REPL | ▼ Sell | Open Market | 37,324 | $190K | 5/18/2026 | View on chart |
| REPL | ▲ Buy | Grant | 251,240 | $0 | 4/1/2026 | View on chart |
| REPL | ▲ Buy | Grant | 200,000 | $0 | 12/19/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 10,000 | $111K | 12/2/2025 | View on chart |
| RVMD | ▲ Buy | Grant | 3,142 | $0 | 6/26/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 25,105 | $202K | 5/20/2025 | View on chart |
| REPL | ▲ Buy | Grant | 166,667 | $0 | 4/1/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 10,000 | $124K | 12/16/2024 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 5,000 | $124K | 10/31/2024 | View on chart |
| RVMD | ▼ Sell | Open Market | 5,000 | $271K | 10/31/2024 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 2,155 | $36K | 7/9/2024 | View on chart |
| RVMD | ▼ Sell | Open Market | 2,155 | $95K | 7/9/2024 | View on chart |
| RVMD | ▲ Buy | Grant | 4,800 | $0 | 6/20/2024 | View on chart |
| REPL | ▼ Sell | Open Market | 20,194 | $131K | 5/16/2024 | View on chart |
| RVMD | ▼ Sell | Open Market | 2,155 | $80K | 4/10/2024 | View on chart |
| RVMD | ▲ Buy | Option Exercise | 2,155 | $36K | 4/10/2024 | View on chart |
| REPL | ▲ Buy | Grant | 83,335 | $0 | 4/1/2024 | View on chart |
| REPL | ▼ Sell | Open Market | 5,145 | $124K | 6/13/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 553 | $13K | 6/13/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 5,200 | $0 | 6/8/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 15,575 | $281K | 5/16/2023 | View on chart |
| REPL | ▲ Buy | Grant | 40,000 | $0 | 4/1/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 10,500 | $0 | 6/16/2022 | View on chart |
| REPL | ▼ Sell | Open Market | 10,687 | $156K | 5/16/2022 | View on chart |
| REPL | ▲ Buy | Grant | 52,500 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views
Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.